Olli Kallioniemi

Abstract Clinical implementation of patient cell-based drug testing is hampered by inconsistencies and irreproducible results. Using linear mixed models and drug response data from four cohorts of patients with acute myeloid leukemia (n = 993 samples), we identified sources of variability in ex vivo drug sensitivity testing across the studies.

Abstract FLT3-mutated acute myeloid leukemia (AML) remains difficult to treat due to frequent resistance to FLT3 inhibitors like midostaurin. In this study, we observed a progenitor-like CD38+CD45RA+ leukemic cell population that may be associated with midostaurin resistance. Midostaurin-resistant cells display disrupted membrane architecture and a shift in signaling from STAT5 to PI3K/AKT, favoring survival over apoptosis.

Abstract Circular RNAs (circRNAs) have emerged as important regulators in cancer biology, but their roles in acute myeloid leukemia (AML) remain poorly characterized due to limited sample sizes and technical challenges in RNA sequencing. Here, we analyze RNA-sequencing data from 315 Swedish AML patients to create the most comprehensive circRNA profile in AML to date.